<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2006-06-01</periodOfReport>

    <dateOfOriginalSubmission>2006-06-14</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000887708</issuerCik>
        <issuerName>CARACO PHARMACEUTICAL LABORATORIES LTD</issuerName>
        <issuerTradingSymbol>CPD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001197089</rptOwnerCik>
            <rptOwnerName>SUN PHARMACEUTICAL INDUSTRIES LTD</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>SPARC, TANDALJA</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>VADODARA, GUJARAT</rptOwnerCity>
            <rptOwnerState>K7</rptOwnerState>
            <rptOwnerZipCode>390 020</rptOwnerZipCode>
            <rptOwnerStateDescription>INDIA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001197088</rptOwnerCik>
            <rptOwnerName>SUN PHARMA GLOBAL INC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>AKARA BUILDING</rptOwnerStreet1>
            <rptOwnerStreet2>24 DE CASTRO STREET,WILKHAMS CLAY 1 ROAD</rptOwnerStreet2>
            <rptOwnerCity>TOWN TARTOLA</rptOwnerCity>
            <rptOwnerState>D8</rptOwnerState>
            <rptOwnerZipCode></rptOwnerZipCode>
            <rptOwnerStateDescription>VIRGIN ISLANDS, BRITISH</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001249644</rptOwnerCik>
            <rptOwnerName>SHANGHVI DILIP S</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SUN PHARMACEUTICAL INDUSTRIES LD.</rptOwnerStreet1>
            <rptOwnerStreet2>MAHAL INDUSTRIES ESTATE, MAHAKALI CAVES</rptOwnerStreet2>
            <rptOwnerCity>ANDHARI (EAST), MUMBIA</rptOwnerCity>
            <rptOwnerState>K7</rptOwnerState>
            <rptOwnerZipCode>400 093</rptOwnerZipCode>
            <rptOwnerStateDescription>INDIA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>(Chairman of the Board)</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Series B. Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2006-06-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>544000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2009-06-01</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>544000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>11424000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F4"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Series B preferred shares are convertible into common stock after three years (or immediately upon a change in control)
 on a one-to-one basis.</footnote>
        <footnote id="F2">Sun Pharma Global, Inc. (&quot;Sun Global&quot;) earns 544,000 shares of Series B Preferred Stock for each technology transfer to
 Caraco of a generic drug by Sun Global when such drug passes its bioequivalency studies.  In the event of the dissolution of
Caraco, such shares have a preference equal to the value attributed to them on the dates on which they were earned. The value
 attributed as of June 1,  2006 was $8.05.</footnote>
        <footnote id="F3">The shares of Series B Preferred Stock remain outstanding until such time as they are converted into Common Stock.</footnote>
        <footnote id="F4">These shares are owned directly by Sun Global, Inc., which is a wholly-owned subsidiary of Sun Pharmaceutical Industries
 Limited (&quot;Sun&quot;).  Dilip S. Shanghvi is the controlling shareholder of Sun.</footnote>
    </footnotes>

    <remarks>See Exhibit Index

Exhibit 99.1 Power of Attorney
Exhibit 99.2 Certified copy of Board resolution of Sun Pharmaceutical Industries, Ltd.
Exhibit 99.3 Certified copy of Board resolution of Sun Pharma Global, Inc.

This Form 4 has been amended only to add certified copies of Board resolutions of Sun and Sun Global relating to the power of
 attorney.</remarks>

    <ownerSignature>
        <signatureName>/s/ Jayesh Shah as attorney-in-fact, for Dilip S. Shanghvi, Chairman and Managing Director of Sun</signatureName>
        <signatureDate>2006-07-11</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Jayesh Shah as attorney-in-fact, for Dilip S. Shanghvi, Director of Sun Global</signatureName>
        <signatureDate>2006-07-11</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Jayesh Shah as attorney-in-fact, for Dilip S. Shanghvi</signatureName>
        <signatureDate>2006-07-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
